Stocktoria
Neuphoria Therapeutics Inc. NEUP
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1999-12-21
Neuphoria Therapeutics Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Operating margin | -1401.1% | -7.2% | — | — |
| Net margin | -1145.7% | -2.4% | — | — |
| Return on assets | -46.9% | -1.3% | -56.0% | -74.9% |
| Return on equity | -54.7% | -1.9% | -88.6% | -97.1% |
| Current ratio | 27.85 | 3.56 | 3.45 | 4.87 |
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.